An Effect of the PAI-1 4G/5G Polymorphism on Cholesterol Levels May Explain Conflicting Associations with Myocardial Infarction and Stroke

Background and Purpose:The gene-encoding plasminogen activator inhibitor type 1 (PAI-1) has a common 4G/5G ‘functional’ polymorphism, and people homozygous for the 4G allele have higher PAI-1 plasma concentrations. The 4G/4G genotype is associated with increased risk of myocardial infarction but paradoxically protects against stroke. We hypothesized that this paradox may be explained via an effect of the PAI-1 polymorphism on plasma lipids. Methods: We studied 71 consecutive Italian patients referred to our Institute for first stroke or vascular cognitive impairment. PAI-1 gene 4G/5G polymorphism, total plasma cholesterol, plasma triglycerides, sex, age, smoking, oral contraceptive use, statin therapy, hypertension, diabetes, and history of myocardial infarction were examined. Results:The 4G/4G genotype was significantly associated with high cholesterol (p = 0.003) but not with triglycerides (p = 0.39). Adjusted odds ratios were: 5.8 for 4G/4G vs. 4G/5G (95% CI, 3.1–23.0), and 15.9 for 4G/4G vs. 5G/5G (95% CI, 2.4–105.0). Conclusions:This finding may explain the involvement of the PAI-1 polymorphism in the clustering of atherothrombotic risk factors, and why people with the 4G/4G genotype are at increased risk for myocardial infarction. Stroke is not so clearly related to hypercholesterolemia and other effects of the 4G/4G genotype (perhaps increased PAI-1 expression) may protect against stroke.

[1]  C. Ladenvall,et al.  Fibrinolytic Gene Polymorphism and Ischemic Stroke , 2005, Stroke.

[2]  A. Hamsten,et al.  Plasminogen Activator Inhibitor-1 4G/5G Polymorphism and Risk of Stroke: Replicated Findings in Two Nested Case–Control Studies Based on Independent Cohorts , 2005, Stroke.

[3]  S. Thompson,et al.  Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. , 1995, The New England journal of medicine.

[4]  E. Parati,et al.  Genetic and Plasma Markers of Venous Thromboembolism in Patients with High Grade Glioma , 2004, Clinical Cancer Research.

[5]  M. Olivier.  A haplotype map of the human genome. , 2003, Nature.

[6]  M. Olivier.  A haplotype map of the human genome , 2003, Nature.

[7]  W. Armstead,et al.  Plasminogen Activators Contribute to Impairment of Hypercapnic and Hypotensive Cerebrovasodilation After Cerebral Hypoxia/Ischemia in the Newborn Pig , 2005 .

[8]  B. Hedblad,et al.  Effects of Cholesterol and Inflammation-Sensitive Plasma Proteins on Incidence of Myocardial Infarction and Stroke in Men , 2002, Circulation.

[9]  S E Humphries,et al.  Genetic determinants of arterial thrombosis. , 1994, Bailliere's best practice & research. Clinical haematology.

[10]  A. Bitto,et al.  Association between serum paraoxonase (PON1) gene promoter T(-107)C polymorphism, PON1 activity and HDL levels in healthy Sicilian octogenarians , 2004, Experimental Gerontology.

[11]  J. Banga,et al.  Editorial comment-- genetic make-up for increased PAI-1 expression protects against stroke. , 2003, Stroke.

[12]  S. Thompson,et al.  Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities. , 1996, Circulation.

[13]  P. Grant,et al.  Plasminogen-activator inhibitor type 1 and coronary artery disease. , 2000, The New England journal of medicine.

[14]  David Lee Gordon,et al.  Classification of Subtype of Acute Ischemic Stroke: Definitions for Use in a Multicenter Clinical Trial , 1993, Stroke.

[15]  J. Bamford,et al.  Determinants of Plasminogen Activator Inhibitor-1 in South Asians with Ischaemic Stroke , 2002, Cerebrovascular Diseases.

[16]  D. Grobbee,et al.  The 4G5G polymorphism in the gene for PAI-1 and the circadian oscillation of plasma PAI-1. , 2003, Blood.

[17]  S. Ebrahim,et al.  What can mendelian randomisation tell us about modifiable behavioural and environmental exposures? , 2005, BMJ : British Medical Journal.

[18]  M. Lai,et al.  4G/5G promoter polymorphism of plasminogen activator inhibitor-1, lipid profiles, and ischemic stroke. , 2003, The Journal of laboratory and clinical medicine.

[19]  A. Hamsten,et al.  Plasminogen Activator Inhibitor-1 Gene Implicated in the Impaired Fibrinolysis of Very-low-density Lipoprotein Response Element in the Promoter Region of the Human , 2022 .

[20]  G. Donnan,et al.  Stroke and cholesterol: weakness of risk versus strength of therapy. , 2004, Stroke.

[21]  Sae-Yong Hong,et al.  4G/5G Polymorphism of the Plasminogen Activator Inhibitor-1 Gene and Insertion/Deletion Polymorphism of the Tissue-Type Plasminogen Activator Gene in Atherothrombotic Stroke , 2001, Cerebrovascular Diseases.

[22]  P. Grant,et al.  Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. , 2000, Blood.